Latest news with #ClinicalTrials
The Independent
7 hours ago
- Health
- The Independent
New daily weight loss pill to rival injections
A new daily Weight Loss pill, amycretin, developed by Novo Nordisk, has shown promising results in initial studies. In trials, patients receiving weekly amycretin injections lost an average of 24.3 percent of their body weight over 36 weeks. Patients taking daily amycretin tablets achieved an average w eight loss of 13.1 percent over 12 weeks. Amycretin works by targeting GLP-1 and amylin receptors to help control blood sugar and appetite. Side effects, including nausea and vomiting, were reported as mostly mild to moderate and resolved by the end of treatment.
Yahoo
2 days ago
- Business
- Yahoo
Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions
Presentations and panel discussions to provide deeper dives into the clinical outcomes from Insulet's groundbreaking SECURE-T2D and RADIANT trials Real-world evidence around glycemic outcomes from more than 23,000 people with type 2 diabetes using Omnipod 5 in the United States will also be shared Booth activities include podcasts, hands-on demonstrations led by clinical experts, and immersive experiences, including a comic book featuring a new hero with type 1 diabetes ACTON, Mass., June 19, 2025--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its planned activities during the American Diabetes Association (ADA) 85th Scientific Sessions taking place June 20 – 23, 2025 at the McCormick Place Convention Center in Chicago, Illinois. "We are thrilled to share more details that dive deeper into the clinical outcomes from our groundbreaking SECURE-T2D and RADIANT trials, as well as the real-world outcomes we are seeing, especially with type 2 diabetes," said Dr. Trang Ly, MBBS, FRACP, PhD, Insulet Senior Vice President and Chief Medical Officer. "We are also looking forward to many conversations with healthcare providers about what the outcomes mean, with practical insights on how to optimize therapy." Insulet shared results of the first large pivotal trial of Automated Insulin Delivery (AID) in type 2 diabetes (SECURE-T2D) at last year's ADA conference. In March, Insulet presented results of the first randomized controlled trial to assess the direct transition from multiple daily injections (MDI) to AID in adults and children with type 1 diabetes not meeting glycemic targets with injections (RADIANT). Presentations at ADA this week will provide richer insights into both trials and more. Conference Activities: Dr. Ly will lead a panel discussion, "Setting the Standard with Omnipod 5: Remarkable Results with Unmatched Simplicity," on Sunday, June 22 from 10:15 – 11:00 AM CT in the conference product theater. She will be joined by Dr. Anders L. Carlson, MD, Associate Executive Director, International Diabetes Center, Director, HealthPartners Diabetes Program, and Associate Professor, University of Minnesota Medical School; Dr. Gregory Forlenza, MD, MS, Associate Professor of Pediatrics, Director of Pediatric Diabetes Technology Research, Barbara Davis Center for Diabetes at the University of Colorado Anschutz Medical Campus; and Dr. Emma Wilmot, MB ChB BSc (hons), PhD, FRCP, Associate Professor, University of Nottingham, Honorary Consultant Diabetologist, University Hospitals of Derby and Burton NHS Trust, Royal Derby Hospital UK. They will have an interactive conversation around several thought-provoking case studies designed to challenge conventional thinking and therapeutic approaches. Dr. Ly will also provide a high-level overview of Insulet's innovation roadmap. Additionally, on Saturday, June 21, there will be a Diabetes Learning Byte session, "Go Beyond GLP-1 Therapy in Type 2 Diabetes with Omnipod 5," from 11:00 AM – 11:20 AM CT at booth 927 with Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner, Henry Ford Health Division of Endocrinology, Diabetes, Bone and Mineral Disease; and Leslie Barrett, MS, RD, CDCES, Director of Medical Affairs, Insulet. Oral Presentations Friday, June 20, Session: 5:30 – 6:30 PM CT, Presentation 5:45 – 6:00 PM CT (W184A-D) 130-OR– Real-World Glycemic Outcomes in Adults with Type 2 Diabetes (T2D) Using the Omnipod 5 Automated Insulin Delivery (AID) System with Dr. Sean Oser Saturday, June 21, Session: 1:30 – 3:00 PM CT, Presentation 2:00 – 2:15 PM CT (W185A-D) 155-OR– Reduced Perceived Diabetes Distress with the Omnipod 5 Automated Insulin Delivery (AID) System in Adults with Type 2 Diabetes (T2D) – Analysis of the SECURE-T2D Study with Dr. Kristin Castorino Monday, June 23, Session: 1:30 – 3:00 PM CT, Presentation 2:45 – 3:00 PM CT (W183A) 314-OR– Improved Outcomes Across Baseline Time-in-Range Levels with the Omnipod 5 AID System Compared with Multiple Daily Injections (MDI) in Type 1 Diabetes (T1D): Analysis of the RADIANT Study with Dr. Emma Wilmot Poster Presentations The following poster presentations will be held from 12:30 – 1:30 PM CT in the Poster Hall (Hall F1) during the weekend. Saturday, June 21 [945-P] – Improved Glycemic Outcomes with the Omnipod 5 AID System in Adults with Type 2 Diabetes (T2D) Previously Using Basal without Bolus Insulin: Sub-analysis of the SECURE-T2D Study with Dr. Anders Carlson [937-P] – Successful Transition from Multiple Daily Injections (MDI) to Automated Insulin Delivery (AID): Real-world Glycemic Outcomes among People with Diabetes Using the Omnipod AID System with Dr. Grazia Aleppo [958-P] – Impact of Insulin Therapy Technology on Health-Related Quality of Life in Adults with Type 1 Diabetes: A Health Utility Study of Five Forms of Therapy with Colin Hopley, MPH, Insulet Sunday, June 22 [2011-LB] – iPhone App Adoption Improves Bolusing Frequency in Adolescents and Young Adults with Type 1 Diabetes (T1D): Insights from Real-World Omnipod® 5 Automated Insulin Delivery (AID) System Use with Dr. Gregory Forlenza Booth Activities: Podcast recordings for Beyond the Bolus, Within Range will be conducted from Insulet's booth (1218). Also, a Baird hosted webcast, "ADA Recap Interview with Dr. Trang Ly," will be facilitated by Sr. Research Analyst, Jeff Johnson. This will take place on Monday, June 23, at 11:00 AM CT. The interview will feature a recap of highlights, new clinical data, and updates from ADA. A link to the webcast will be available on the Investor Relations section of the Company's website at under "Events and Presentations," and will be archived for future replay. Insulet will bring immersive booth experiences that showcase how Omnipod 5 is transforming diabetes management. Attendees can engage in hands-on demonstrations led by clinical experts, exploring optimization techniques that support better outcomes. Attendees can also play an educational trivia game to learn how Omnipod 5 brings a whole new level of simplicity and convenience for mealtime insulin dosing. Insulet will also be distributing a new comic book to celebrate representation for the diabetes community. Dyasonic: Sound of Strength featuring a hero with type 1 diabetes. To access the comic book and related materials go to About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit: and ©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. All other trademarks are the property of their respective owners. The use of third-party trademarks does not constitute an endorsement or imply a relationship or other affiliation. View source version on Contacts Investor Relations: June LazaroffSenior Director, Investor Relations(978) 600-7717jlazaroff@ Media: Angela Geryak WiczekSenior Director, Corporate Communications(978) 932-0611awiczek@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
22-05-2025
- Health
- Medscape
Conference MDAngle: ASCO 2025 Early Breast Cancer
Preconference Considerations ASCO 2025: Previewing Updates in Early-Stage Breast Cancer Dr Chavez MacGregor eagerly awaits the 2025 ASCO Annual Meeting, especially the sessions on early-stage breast cancer. She highlights new data on treatment optimization for HER2-positive disease and updates on managing HR-positive breast cancer in premenopausal women, including results from key trials like SOFT, TEXT, and ASTRRA. Dr Chavez MacGregor is also looking forward to sessions on circulating tumor DNA and emerging therapies for improving quality of life during endocrine treatment. Quick Clinical Takeaways Coming soon: Dr Chavez MacGregor will share new data and insights on early breast cancer directly after ASCO. How Will My Patients Benefit? Coming soon: Reflections from Dr Chavez MacGregor on how new data from ASCO will affect her patients with early breast cancer. Lead image: Medscape
Yahoo
20-05-2025
- Health
- Yahoo
CAR-T cell therapy is revolutionising cancer treatment – here's how it works
Personalised medicine is already a reality in clinical practice, and CAR-T cell therapy is one of its most promising tools. This innovative approach, which involves genetically modifying the cells of the immune system, is transforming the way we treat not only cancer, but also other diseases. The CAR-T revolution is widely documented, with more than 1,000 clinical trials currently underway worldwide according to the ClinicalTrials platform. This reflects an enormous amount of scientific and medical interest. To understand why it is of such interest, we first need to know what the function of a T-lymphocyte is. These cells belong to the immune system, and are responsible for finding and eliminating cells that are infected or have become abnormal, such as cancerous cells. We can think of them as the body's police force: they recognise when something is wrong, and help to maintain the balance in our body. CAR-T cells are, in essence, T-lymphocytes equipped with a next-generation membrane receptor: a structure specifically designed to recognise and attack tumour cells with a precision and sensitivity far superior to a normal T-cell. The difference is huge, like going from a mid-2000s Nokia phone to the latest iPhone. Thanks to this modification, CAR-T cells can generate an immune response up to 1,000 times stronger than an ordinary lymphocyte. This makes it possible to eliminate cancer cells that do not respond to conventional treatments. But what exactly is this alteration that proves so lethal to cancer cells? CAR-T cells are designed as 'reconnaissance and attack' against cancer, and to do this, they have three main components. There is an external part that acts like a radar, identifying tumour cells; another part that passes through the cell membrane to transmit the signal inwards, and an internal part that triggers the T-cell response, activating its attack. Although this basic design has already proven very powerful, researchers continue to improve it, both to make it even more effective and to prevent cells from becoming exhausted before they are able to kill off every last tumour cell. Therapeutic options for many patients have multiplied thanks both to the ability to develop these cells ex vivo – in the laboratory – and to advances in gene editing. To date, there are 7 CAR-T therapies which are authorised for use in patients. Despite their efficacy, these therapies are not yet available to all patients due to their high cost and associated risks. This underlines the need to improve both their safety and accessibility. Moreover, although CAR-T has been very successful in treating leukaemias and myelomas, its application in solid tumours remains a challenge. In these cases, the tumour microenvironment imposes additional barriers: T cells must pass through dense matrices that hinder their motility. The acidic environment also compromises their functionality, and nutrient shortages can lead to cellular exhaustion. Such factors have so far limited the success of CAR-T therapies in solid tumours, but researchers continue to explore new ways to overcome these difficulties. One such method involves combining chemotherapy and radiotherapy to enable T-cells to reach tumour cells. Combining CAR-T with immune checkpoint inhibitors – drugs that block certain signals used by tumour cells to avoid being attacked by the immune system – could also improve their effectiveness in such hostile environments. However, it is not always possible to obtain lymphocytes from the patient, either due to limitations in quality or quantity or clinical conditions that make collection difficult. To address this, research is being done into allogeneic therapies that use 'off the shelf' CAR-T cells. These use T-cells from healthy donors, and are stored ready for use when needed. These methods not only reduce production times and costs, but also expand access to such treatments to a wider range of patients. Although there are still several hurdles to overcome, the main challenge is the expanding the application of CAR-T cells to other cancers, especially solid tumours, which could benefit from these therapies. Examples include glioblastoma and metastatic ovarian cancer. In the case of glioblastoma (a type of brain tumour), specific targets such as B7H3 or EGFRvIII are being investigated. These antigens are only expressed on tumour cells, improving the accuracy of these therapies. Also under study are new delivery modes that cross the blood-brain barrier (a barrier that regulates the passage of what can and cannot reach the brain) and ways to modulate inflammation, which is critical in treating brain tumours. For metastatic ovarian cancer, for which there is currently no curative treatment, CAR-Ts offer a promising alternative. Clinical trials have shown encouraging results by targeting certain new tumour markers. Moreover, CAR-T therapies are not only being applied in oncology. They are also being investigated for use in the treatment of autoimmune diseases, with trials underway for diseases such as rheumatoid arthritis. This opens up new possibilities for the future use of these therapies. CAR-T's advances, both consolidated and those on the horizon, have led the pharmaceutical industry to boost its investment in these therapies. Currently, the CAR-T cell therapeutics market is estimated to grow from $10.39 billion in 2024 to $128.55 billion in 2032. The true potential of these therapies is yet to be discovered, and may lie in their effective application against solid tumours. However, one thing is for certain: what until recently seemed a futuristic concept is now a reality. Personalised medicine is here to stay, and CAR-T therapies are leading the way. Este artículo fue publicado originalmente en The Conversation, un sitio de noticias sin fines de lucro dedicado a compartir ideas de expertos académicos. Lee mas: Joe Biden has prostate cancer with bone spread – an oncologist explains what you need to know How 7,000 steps a day could help reduce your risk of cancer How optical fibres are transforming cancer care Lydia Begoña Horndler Gil no recibe salario, ni ejerce labores de consultoría, ni posee acciones, ni recibe financiación de ninguna compañía u organización que pueda obtener beneficio de este artículo, y ha declarado carecer de vínculos relevantes más allá del cargo académico citado.
Daily Mail
14-05-2025
- Health
- Daily Mail
SARAH VINE: I have tried all the weight loss jabs from Ozempic to Wegovy to Mounjaro... and THIS is the one that's easily the best
Every age has its great rivalries: Rome vs Carthage, Mozart vs Salieri, Shakespeare vs Marlowe, the Rolling Stones vs The Beatles. For us, halfway through the 2020s, it's Mounjaro vs Ozempic, the battle of the fat jabs. In the first ever head-to-head clinical trial, tirzepatide (the active ingredient in Mounjaro) has been found to be almost 50 per cent more effective than semaglutide (the active ingredient in Ozempic and Wegovy).
